Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by funky99on May 14, 2015 11:16am
152 Views
Post# 23728343

RE:RE:RE:RE:RE:May 2015 - BLOOM BURTON CONFERENCE PRESENTATION

RE:RE:RE:RE:RE:May 2015 - BLOOM BURTON CONFERENCE PRESENTATIONCasusFortuitus I trust you also looked at the official news release as well from Antibe Therapeutics to complete your DD.  

Antibe testing confirms ATB-346 efficacy at lower doses
2015-04-17 07:50 ET - News Release
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aATE-2268567&symbol=ATE&region=C

I also think investors do not based their investment on SH bullboards. With the tight float here and the way it has been trading, the investors already secured their position imo. The rest is only some traders.

Personnally, I base my investment or trades on charts/technical analysis, facts and data/news release and my own DD. Good luck with your investment/trades or shorts ;) I am long with ATE and nothing so far will change my decision. 





Bullboard Posts
Dealroom for high-potential pre-IPO opportunities